Show Summary Details
Page of

Smoking cessation 

Smoking cessation
Chapter:
Smoking cessation
Author(s):

Onn Min Kon

and Susannah A.A. Bloch

DOI:
10.1093/med/9780199549146.003.0005
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 February 2020

Smoking cessation is currently the only intervention that causes a slowing in the natural history of an accelerated loss of forced expiratory volume in 1s (FEV1) in COPD.

The addictive properties of nicotine in tobacco are mediated primarily through the release of dopamine in the nucleus accumbens via nicotinic receptors.

Smoking advice should be carried out regularly by all health professionals and has been shown to be effective.

Both behavioural therapy and pharmacological therapies have been shown to be effective in achieving smoking cessation.

Nicotine replacement, bupropion, and varenicline are first-line agents that increase the likelihood of successful smoking cessation.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.